A paradigm shift in
cellular-based therapy
for regenerative medicine
Our platform technologies Progenza™ and Sygenus are novel approaches to pain, that leverage stem cells as cellular pharmacies and utilise Secretome as a therapeutic agent.
Q&A with Dr Charlotte Morgan, Head of R&D at Regeneus
[video src="https://regeneus.com.au/wp-content/uploads/2021-03-22_11-29-25.mp4" /] Q. What is your background and experience in the regenerative medicine space and how did this lead you to Regeneus? A. I arrived in Australia in 2001 with an extensive background in biotechnology product development. Before…
Regeneus to Present at 2021 Virtual Cell & Gene Meeting on the Mediterranean
Regeneus Ltd (ASX: RGS) (Regeneus or the Company) announced today that Regeneus Chief Executive Officer Karolis Rosickas will present at the annual Cell & Gene Meeting on the Mediterranean to be held virtually April 6-9. Organized by the Alliance for Regenerative Medicine, the Cell & Gene…
Regeneus (ASX:RGS) Company Update Investor Webcast Recording
During a webcast for investors on Wednesday 3 March 2021, Regeneus CEO Karolis Rosickas provided an update on Regeneus, its lead technology platforms Progenza™ and Sygenus, and where the Company is headed in 2021. The second half of the session contained a Q&A where Karolis was joined by,…
Regeneus (ASX:RGS) Company Update Investor Webcast
Regeneus Ltd (ASX: RGS) (Regeneus) invites its shareholders and interested parties to attend a live webcast and Q&A with Regeneus CEO Karolis Rosickas on Wednesday 3 March at 11:00am Australian Eastern Daylight Time (AEDT). During the session, Karolis Rosickas will provide an update on the…
Regeneus Half Year Results H1 FY21
Regeneus' (ASX:RGS) CEO Karolis Rosickas announces the release of the Company's Half Year Results for the period ending 31 December 2020. Read the full report here and the cover note here.
The Science
MSCs and Secretome are the next frontier in targeting pain and inflammation. They combine to make a 'bioactive soup' that repurposes inflamed tissue at a site of injury, helping reduce pain and further tissue damage.
Product Pipeline
Our platform technologies Progenza™ and Sygenus represent a potential major paradigm shift in treating pain and inflammation at its source, by harnessing the power of MSCs and Secretome.
IP and Manufacturing
Our manufacturing techniques ensure cost-effective and high batch-to-batch consistency in our stem cell production. Alongside our research partners, we can scale up our platform technologies to meet market demand.
Partnering with us
Regeneus is constantly looking for partners and research collaborators.
Contact us for more information.